


Name	Yoshikazu Inoue, M.D., Ph.D.	
Country	JAPAN	
Organization	#1 Osaka Anti-tuberculosis Association Osaka Fukujuji Hospital, Osaka, Japan #2 National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan	
Current Position	#1 Advisor #2 Visiting researcher	

Educational Background

- 1977-1983 Ehime University, School of Medicine (M.D.)
- 1984-1988 Graduate School, Ehime University, School of Medicine (Ph.D.)
- 1988-1991 Department of Internal Medicine, Respiratory Medicine, National Ehime Hospital
- 1991-1997 Acting Assistant Professor, the 2nd Department of Internal Medicine Ehime, University, School of Medicine
- 1994-1997 Post graduate fellow, University of Colorado, Health Science Center, National Jewish Center for Immunology and Respiratory Medicine, Occupational and Environmental Section, Pulmonary Division (Denver, Colorado, USA)
- 1997-1998 Chief Physician, Internal Medicine, National Kinki-Chuo Hospital for Chest Diseases, Osaka, Japan
- 1998-2001 General Manager, Immunology Laboratory, Department of Clinical Research, and Chief Physician, Internal Medicine, National Kinki-Chuo Hospital for Chest Diseases, Osaka, Japan
- 2001-2004 Director of Department of Rerspiratory Failure, Clinical Research Center, National Kinki-Chuo Hospital for Chest Diseases, Osaka, Japan
- 2004 Director of Department of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
- 2006-2011 Invited Associate Proffessor, Infection, Immunology and Oncology Cooperating Course, Graduate School of Medicine, Osaka University, Osaka, Japan
- 2011-2023 Invited Proffessor, Infection, Immunology and Oncology Cooperating Course, Graduate School of Medicine, Osaka University, Osaka, Japan
- 2014-2023 Executive Director, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
Director, Department of Intractable Lung Diseases (Interstitial Lung Diseases), Head, Division of Tuberculosis Vaccine and Treatment National Hospital Organization Kinki-Chuo Chest Medical Center
- 2014-2023 Group Leader of Respiratory Network of National Hospital Organization
- 2023- Visiting Researcher, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
- 2023- Advisor, Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital

Professional Experiences

- 1983 Medical Doctor, Japan (#273606, May, 24th, 1983)
- 1984 Doctor of Philosophy (Ph.D.), Ehime University, Japan
- 1989- Specialist of Intennal Medicine licenced by Japanese Society of Internal medicine
- 1990- Board Certified Member of Japan Society for Respiratory Endoscopy
- 1991- Board Certified Member of the Japanese Respiratory Society
- 1994- Board Certified Member of The Japanese Circulation Society
- 2004- Senior Fellow of the Japanese Respiratory Society
- 2011- Board Certified Member of The Japanese Society for Tuberculosis And Nontuberculosis Mycobacteriosis

(Social activities)

- 2001- Medical Adviser, J-LAM (Japanese Patients Suport Group for Lymphangioliomyomatosis)

- 2004- Clinical Advisory Board of the Pulmonary Alveolar Proteinosis Foundation (USA)
- 2007-2014 Clinical Science Board or Scientific Advisory Board (Scientific Advisory Board) of LAM Foundation (USA)
- 2010- Clinica Advisory borad of Japanese Patient Suport Group of Pulmonary Alveolar Proteinosis
- 2014- The LAM Foundation (USA) Scientific Advisory Board
- 2014- The LAM Foundation International LAM Clinic, Clinical director
- 2010- The Best Doctors in Japan
- 2015 LAM foundation Scientific Advancement Award (The LAM Foundation, USA)

Professional Organizations

(From 2010)

- 2010-2012 Program committee of Japanese Respiratory Society
- 2010-2013 Board member of ATS/ERS International Multidisciplinary Classification of Idiopathic InterstitialPneumonias
- 2010-2011 Board member of JRS, Guidance for Idiopathic Interstitial Pneumonias
- 2011-2017 Member of World Association of Sarcoidosis and Other Granulomatous Disorders
- 2011-2023 Delegate of Japan Society for Respiratory Endoscopy
- 2012- Member of Fleishner Society
- 2012- Delegate of the Japanese Medical Society for Lung Surfactant and Biological Interface
- 2012-2016 Vise-president of The Osaka Meeting on Diffise Infiltrative Lung Diseases
- 2012-2016 Vise-president of Kinki-division, Japan Society of Sarcoidosis and Other Granulomatous Disorders
- 2013-2023 Delegate of Japanese Respiratory Society
- 2014- Board member of Medical Insurance, Japanese Respiratory Society
- 2015-2017 Secretary of the Fleishner Society
- 2015 President of the Japanese Medical Society for Lung Surfactant and Biological Interface
- 2016-2022 Board Member, Educational Board, Japanese Respiratory Society
- 2016-2018 Editorial Board Member, Japanese Respiratory Society
- 2017-2023 President of Kinki-division, Japan Society of Sarcoidosis and Other Granulomatous Disorders
- 2017- President, Osaka Interstitial Lung Diseases Forum
- 2019-2023 President, The Osaka Meeting on Diffise Infiltrative Lung Diseases
- 2019-2020 President of the Fleishner Society
- 2020-2021 Immediate Past-President of the Fleishner Society
- 2020-2021 President of Japan Society of Sarcoidosis and Other Granulomatous Disorders
- 2022- Delegate of Japan Society of Sarcoidosis and Other Granulomatous Disorders
- 2023- Meritorious Member, Japanese Respiratory Society
- 2023- Special Member, Japan Society for Respiratory Endoscopy

Main Scientific Publications

< Major Scientific Publications from 2018 >

1. Khor YH, Cottin V, Holland AE, **Inoue Y**, McDonald VM, Oldham J, Renzoni EA, Russell AM, Streck ME, Ryerson CJ. Treatable traits: a comprehensive precision medicine in interstitial lung disease. *Eur Respir J*. 2023 Jun 1;2300404. doi: 10.1183/13993003.00404-2023
2. Chua F, Low S, Chai GT, **Inoue Y**, Ong V, Wongkarnjana A, Kawkitinarong K, Song JW, Hamid ZA, Aziz AA, Campomanes M, Maher TM, Molyneaux PL, Syakirin S. Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random? *Lancet Respir Med*. 2023 Apr 4;S2213-2600(23)00125-X. doi: 10.1016/S2213-2600(23)00125-X
3. Fujisawa T, Akiyama N, Morita T, Koyachi T, Matsuda Y, Mori M, Miyashita M, Tachikawa R, Tomii K, Tomioka H, Hagimoto S, Kondoh Y, **Inoue Y**, Suda T. Palliative care for interstitial lung disease: A nationwide survey of pulmonary specialists. *Respirology*. 2023 Mar 22. doi: 10.1111/resp.14493
4. Uehara Y, Tanaka Y, Zhao S, Nikolaidis NM, Pitstick LB, Wu H, Yu JJ, Zhang E, Hasegawa Y, Noel JG, Gardner JC, Koprak EJ, Haffey WD, Greis KD, Guo J, Woods JC, Wikenheiser-Brokamp KA, Kyle JE, Ansong C, Teitelbaum SL, **Inoue Y**, Altinşik G, Xu Y, McCormack FX. Insights into pulmonary phosphate homeostasis and osteoclastogenesis emerge from the study of pulmonary alveolar microlithiasis. *Nat Commun*. 2023 Mar 2;14(1):1205. doi: 10.1038/s41467-023-36810-8.
5. Inoue Y, Wells AU, Song JW, Xu Z, Kitamura H, Suda T, Okamoto M, Müller H, Coeck C, Rohr KB, Kolb M, Brown KK. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. *Respirology*. 2023 Jan 15. doi: 10.1111/resp.14452. Online ahead of print.
6. Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, Corte TJ, Dickinson JL, Glaspole I, Moodley YP, Vasakova MK, Bendstrup E, Davidsen JR, Borie R, Crestani B, Dieude P, Bonella F, Costabel U, Gudmundsson G, Donnelly SC, Egan J, Henry MT, Keane MP,

- Kennedy MP, McCarthy C, McElroy AN, Olaniyi JA, O'Reilly KMA, Richeldi L, Leone PM, Poletti V, Puppo F, Tomassetti S, Luzzi V, Kokturk N, Mogulkoc N, Fiddler CA, Hirani N, Jenkins G, Maher TM, Molyneux PL, Parfrey H, Braybrooke R, Blackwell TS, Jackson PD, Nathan SD, Porteous MK, Brown KK, Christie JD, Collard HR, Eickelberg O, Foster EE, Gibson KF, Glassberg M, Kass D, Kropski JA, Lederer D, Linderholm AL, Loyd J, Mathai SK, Montesi SB, Noth I, Oldham JM, Palmisciano AJ, Reichner CA, Rojas M, Roman J, Schluger N, Shea BS, Swigris JJ, Wolters PJ, Zhang Y, Prele CMA, Enghelmayer JI, Otaola M, Ryerson CJ, Salinas M, Sterclova M, Gebremariam TH, Myllärniemi M, Carbone R, Furusawa H, Hirose M, **Inoue Y**, Miyazaki Y, Ohta K, Ohta S, Okamoto T, Kim DS, Pardo A, Selman M, Aranda AU, Park MS, Park JS, Song JW, Molina-Molina M, Planas-Cerezales L, Westergren-Thorsson G, Smith AV, Manichaikul AW, Kim JS, Rich SS, Oelsner EC, Barr RG, Rotter JI, Dupuis J, O'Connor G, Vasan RS, Cho MH, Silverman EK, Schwarz MI, Steele MP, Lee JS, Yang IV, Fingerlin TE, Schwartz DA; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants. *Am J Respir Crit Care Med*. 2023 Jan 5. doi: 10.1164/rccm.202207-1331OC
7. Cottin V, Selman M, **Inoue Y**, Wong AW, Corte TJ, Flaherty KR, Han MK, Jacob J, Johannson KA, Kitaichi M, Lee JS, Agusti A, Antoniou KM, Bianchi P, Caro F, Florenzano M, Galvin L, Iwasawa T, Martinez FJ, Morgan RL, Myers JL, Nicholson AG, Occhipinti M, Poletti V, Salisbury ML, Sin DD, Sverzellati N, Tonia T, Valenzuela C, Ryerson CJ, Wells AU. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. *Am J Respir Crit Care Med*. 2022 Aug 15;206(4):e7-e41. doi: 10.1164/rccm.202206-1041ST. PMID: 35969190
 8. Marinescu DC, Raghu G, Remy-Jardin M, Travis WD, Adegunsoye A, Beasley MB, Chung JH, Churg A, Cottin V, Egashira R, Fernández Pérez ER, **Inoue Y**, Johannson KA, Kazerooni EA, Khor YH, Lynch DA, Müller NL, Myers JL, Nicholson AG, Rajan S, Saito-Koyama R, Troy L, Walsh SLF, Wells AU, Wijsenbeek MS, Wright JL, Ryerson CJ. Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. *Chest*. 2022 Jun 20:S0012-3692(22)01102-3. doi: 10.1016/j.chest.2022.06.013. Online ahead of print.
 9. Ganesh Raghu, Martine Remy-Jardin, Luca Richeldi, Carey C Thomson, **Yoshikazu Inoue**, Takeshi Johkoh, Michael Kreuter, David A Lynch, Toby M Maher, Fernando J Martinez, Maria Molina-Molina, Jeffrey L Myers, Andrew G Nicholson, Christopher J Ryerson, Mary E Strek, Lauren K Troy, Marlies Wijsenbeek, Manoj J Mammen, Tanzib Hossain, Brittany D Bissell, Derrick D Herman, Stephanie M Hon, Fayeze Kheir, Yet H Khor, Madalina Macrea, Katerina M Antoniou, Demosthenes Bouros, Ivette Buendia-Roldan, Fabian Caro, Bruno Crestani, Lawrence Ho, Julie Morisset, Amy L Olson, Anna Podolanczuk, Venerino Poletti, Moisés Selman, Thomas Ewing, Stephen Jones, Shandra L Knight, Marya Ghazipura, Kevin C Wilson. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.PMID: 35486072
 10. Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. PMID: 35569036
 11. Cottin V, Tomassetti S, Valenzuela C, Walsh S, Antoniou K, Bonella F, Brown KK, Collard HR, Corte TJ, Flaherty K, Johannson KA, Kolb M, Kreuter M, **Inoue Y**, Jenkins G, Lee JS, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers J, Nathan SD, Poletti V, Quadrelli S, Raghu G, Rajan SK, Ravaglia C, Remy-Jardin M, Renzoni E, Richeldi L, Spagnolo P, Troy L, Wijsenbeek M, Wilson KC, Wuyts W, Wells AU, Ryerson C. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. *Am J Respir Crit Care Med*. 2022 Mar 30. doi: 10.1164/rccm.202111-2607PP.
 12. D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara H, Takeshita A, Nishihama K, Okano T, Saiki H, Okano Y, Tomaru A, Fridman D'Alessandro V, Shiraiishi M, Mizoguchi A, Ono R, Ohtsuka J, Fukumura M, Nosaka T, Mi X, Shukla D, Kataoka K, Kondoh Y, Hirose M, Arai T, **Inoue Y**, Yano Y, Mackie RI, Cann I, Gabazza EC. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. *Nat Commun*. 2022 Mar 23;13(1):1558. doi: 10.1038/s41467-022-29064-3.
 13. Brown KK, **Inoue Y**, Flaherty KR, Martinez FJ, Cottin V, Bonella F, Cerri S, Danoff SK, Joanneau S, Goeldner RG, Schmidt M, Stowasser S, Schlenker-Herceg R, Wells AU. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. *Respirology*. 2022 Feb 27. doi: 10.1111/resp.14231.
 14. Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Carvalho CRR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR. COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition. *Chest*. 2021 Dec 21:S0012-3692(21)05166-7.
 15. Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, **Inoue Y**. The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases. *Eur Respir J*. 2021 Nov 11:2101790. doi: 10.1183/13993003.01790-2021
 16. Lancaster L, Bonella F, **Inoue Y**, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. *Respirology*. 2021 Oct 5. doi: 10.1111/resp.14154. Online ahead of print.
 17. **Inoue Y**, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. *Respir Med*. 2021 Aug 12;187:106574.
 18. Flaherty KR, Wells AU, Cottin V, Devaraj A, **Inoue Y**, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD trial investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. *Eur Respir J*. 2021 Sep 2:2004538.
 19. Enomoto N, Homma S, Inase N, Kondoh Y, Saraya T, Takizawa H, **Inoue Y**, Ishii H, Taguchi Y, Izumi S, Yamano Y, Tanino Y, Nishioka Y, Toyoshima M, Yokomura K, Imokawa S, Koshimizu N, Sano T, Akamatsu T, Mukae H, Kato M, Hamada N, Chiba H, Akagawa S, Muro S, Uruga H, Matsuda H, Kaida Y, Kanai M, Mori K, Masuda M, Hozumi H, Fujisawa T, Nakamura Y, Ogawa N, Suda T. Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial

- pneumonias. *Thorax*. 2021 Jul 16;thoraxjnl-2020-216263. doi: 10.1136/thoraxjnl-2020-216263. Online ahead of print.
20. Sakaue S, Yamaguchi E, **Inoue Y**, Takahashi M, Hirata J, Suzuki K, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Miyawaki S, Dofuku S, Maeda Y, Nii T, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Sonehara K, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Iбата H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. *Nat Commun*. 2021 Feb 15;12(1):1032. doi: 10.1038/s41467-021-21011-y.
 21. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raouf S, Rubin GD, Powell C, **Inoue Y**, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. *Chest*. 2021 Mar;159(3):1107-1125.
 22. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raouf S, Rubin GD, Powell C, **Inoue Y**, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. *Radiology*. 2021 Mar;298(3):550-566.
 23. Trapnell BC, **Inoue Y**, Bonella F, Morgan C, Jouneau S, Bendstrup E, Campo I, Papis SA, Yamaguchi E, Cetinkaya E, Ilkovich MM, Kramer MR, Veltkamp M, Kreuter M, Baba T, Ganslandt C, Tarnow I, Waterer G, Jauhikainen T; IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. *N Engl J Med*. 2020 Oct 22;383(17):1635-1644
 24. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, **Inoue Y**, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020 Aug 1;202(3):e36-e69
 25. Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San José Estépar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, **Inoue Y**, Lynch DA. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. *Lancet Respir Med*. 2020 Jul;8(7):726-737.
 26. Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, Hamada N, Taniguchi H, Hattori N, Nishioka Y, Tanizawa K, Johkoh T, Yokoyama T, Mori K, Taguchi Y, Ebina M, Inase N, Hagiwara K, Ohnishi H, Mukae H, **Inoue Y**, Kuwano K, Chiba H, Ohta K, Tanino Y, Sakai F, Sugiyama Y. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. *ERJ Open Res*. 2020 May 26;6(2):00184-2019
 27. Arai T, **Inoue Y**. Is corticosteroid use truly not associated with improved outcomes in AE-IPF? *Respirology*. 2020 Jun;25(6):659
 28. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raouf S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, **Inoue Y**, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Chest*. 2020 Apr 7. pii: S0012-3692(20)30673-5
 29. **Inoue Y**, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. *Chest*. 2020 Apr 5. pii: S0012-3692(20)30569-9
 30. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raouf S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, **Inoue Y**, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*. 2020 Apr 7:201365.
 31. Wells AU, Flaherty KR, Brown KK, **Inoue Y**, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med*. 2020 Mar 5. pii: S2213-2600(20)30036-9
 32. Nakata K, Sugi T, Kuroda K, Yoshizawa K, Takada T, Tazawa R, Ueda T, Aoki A, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Hirano T, Handa T, Hirai T, **Inoue Y**, Arai T, Asakawa K, Sakagami T, Tanaka T, Mikami A, Kitamura N. Validation of a new serum granulocyte-macrophage colony-stimulating factor autoantibody testing kit. *ERJ Open Res*. 2020 Jan 27;6(1). pii: 00259-2019
 33. Liu H, Osterburg AR, Flury J, Swank Z, McGraw DW, Gupta N, Wikenheiser-Brokamp KA, Kumar A, Tazi A, **Inoue Y**, Hirose M, McCormack FX, Borchers MT. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. *JCI Insight*. 2020 Feb 27;5(4). pii: 132048.
 34. Kondoh Y, Azuma A, **Inoue Y**, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S. Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial. *Am J Respir Crit Care Med*. 2020 Jan 9
 35. Varone F, **Inoue Y**, Richeldi L. Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis. *Respirology*. 2020 Jan;25(1):20-22
 36. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, **Inoue Y**, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med*. 2019 Oct 31;381(18):1718-1727
37. Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, **Inoue Y**, Arai T, Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N, Nakata K. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. *N Engl J Med*. 2019 Sep 5;381(10):923-932.
 38. Song JW, Ogura T, **Inoue Y**, Xu Z, Quaresma M, Stowasser S, Stansen W, Crestani B. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON. *Respirology*. 2020 Apr;25(4):410-416.
 39. Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respir Med*. 2019 Sep;7(9):771-779
 40. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, **Inoue Y**, Kondoh Y, Kreuter M, Johansson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2019 Nov 1;200(9):1146-1153
 41. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundry JS, O'Riordan T, Streck ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, **Inoue Y**, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2019 Jul 15;200(2):199-208
 42. Fujisawa T, Mori K, Mikamo M, Ohno T, Kataoka K, Sugimoto C, Kitamura H, Enomoto N, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Hashisako M, Tanaka T, Terasaki Y, Kunugi S, Kitani M, Okuda R, Horiike Y, Enomoto Y, Yasui H, Hozumi H, Suzuki Y, Nakamura Y, Fukuoka J, Johkoh T, Kondoh Y, Ogura T, **Inoue Y**, Hasegawa Y, Inase N, Homma S, Suda T. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. *Eur Respir J*. 2019 May 18;53(5). pii: 1802243
 43. Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, **Inoue Y**, McCormack FX; NIH Rare Lung Disease Consortium. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. *Eur Respir J*. 2019 Apr 4;53(4). pii: 1802066
 44. Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Edahiro R, Hamasaki T, **Inoue Y**; Osaka Acute Exacerbation of Interstitial Pneumonia Research Group. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. *Respirology*. 2019 Jul;24(7):658-666
 45. Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, Young LR, McCormack FX, **Inoue Y**. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. *PLoS One*. 2019 Feb 28;14(2):e0212776
 46. Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, **Inoue Y**. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. *Eur Respir Rev*. 2018 Dec 21;27(150). pii: 180075
 47. Kumar A, Abdelmalak B, **Inoue Y**, Culver D. Blood testing in the diagnosis of pulmonary alveolar proteinosis - Authors' reply. *Lancet Respir Med*. 2018 Nov;6(11):e55
 48. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, **Inoue Y**, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018 Sep 1;198(5):e44-e68
 49. Arai T, **Inoue Y**. Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. *Respirology*. 2018 May;23(5):546-547
 50. Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raoof S, Richeldi L, Ryerson CJ, Ryu JH. Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. *Lancet Respir Med*. 2018 Feb;6(2):e7
 51. Kumar A, Abdelmalak B, **Inoue Y**, Culver DA. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. *Lancet Respir Med*. 2018 Jul;6(7):554-565
 52. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, **Inoue Y**, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med*. 2018 Feb;6(2):138-153